- Home
- STSS vs ACET Comparison
STSS vs ACET Comparison
Compare STSS & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STSS | ACET |
|---|---|---|
| Founded | 2017 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 71.3M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | STSS | ACET |
|---|---|---|
| Price | $1.90 | $8.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $96.67 |
| AVG Volume (30 Days) | ★ 496.6K | 230.6K |
| Earning Date | 11-17-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $306,344.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.65 | $7.15 |
| 52 Week High | $630.01 | $17.44 |
Technical Indicators
Market Signals| Indicator | STSS | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 36.70 | 85.72 |
| Support Level | $1.93 | $7.94 |
| Resistance Level | $2.61 | $8.55 |
| Average True Range (ATR) | 0.20 | 0.35 |
| MACD | 0.07 | 0.60 |
| Stochastic Oscillator | 25.90 | 88.24 |
Price Performance
Historical ComparisonAbout STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes designed to eliminate potentially infectious and accidental needlestick injuries.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.